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SUMMARY
Given its catalytic activity to generate diacylglycerol and inositol 1,4,5-trisphosphate, phospholipase C (PLC)
is implicated in promoting cell growth. However, we found that PLC-b3-deficient mice develop myeloprolif-
erative disease, lymphoma, and other tumors. The mutant mice have increased numbers of hematopoietic
stem cells with increased proliferative, survival, and myeloid-differentiative abilities. These properties are
dependent on Stat5 and can be antagonized by the protein phosphatase SHP-1. Stat5-dependent coopera-
tive transformation by active c-MycandPLC-b3 deficiencywas suggested inmouse lymphomas inPLC-b3/
and in Em-myc;PLC-b3+/ mice and human Burkitt’s lymphoma cells. The same mechanism for malignant
transformation seems to be operative in other human lymphoid and myeloid malignancies. Thus, PLC-b3 is
likely a tumor suppressor.INTRODUCTION
The production and lineage commitment of hematopoietic cells
is controlled by the actions of a multitude of cytokines, growth
factors, and hormones (Kondo et al., 2003). Cell surface recep-
tors bound by these ligands activate several signaling pathwaysincluding the Jak-Stat pathway. This pathway plays a crucial role
in a number of biological functions by activating transcription of
various target genes (Levy and Darnell, 2002; O’Shea et al.,
2002; Schindler et al., 2007). Cytokine stimulation activates
Jak kinases through transphosphorylation and results in tyrosine
phosphorylation of receptor sites, Stats, and other substrates.SIGNIFICANCE
Many hematopoietic malignancies depend on the activity of Stat5 transcription factor. Here, we report a novel Stat5-
suppressive mechanism by which PLC-b3 augments dephosphorylating activity of SHP-1 toward Stat5 by recruiting
SHP-1 and Stat5 to its C-terminal sequence. Abrogation of this suppression leads tomyeloproliferative disease, lymphoma,
and other types of cancer in PLC-b3/ mice. PLC-b3 deficiency or downregulation appears to cooperate with c-Myc to
induce B cell lymphoma in mice and humans. The same mechanism may be operative in human myeloid and lymphoid
tumors. Therefore, the adaptor function of PLC-b3 seems essential to protect the hematopoietic and nonhematopoietic
systems from tumor development.Cancer Cell 16, 161–171, August 4, 2009 ª2009 Elsevier Inc. 161
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PLC-b3 as a Potential Tumor SuppressorFollowing tyrosine phosphorylation, Stats homo- or heterodi-
merize, translocate to the nucleus, and activate gene expression
through sequence-specific response elements.
To date, sevenmammalian Stat family membershavebeen iden-
tified: Stats 1, 2, 3, 4, 5A, 5B, and 6; Stat5 is encoded by two
recently duplicated genes, Stat5A and Stat5B, with 96%
sequence identity (Muietal., 1995).Stat5 plays a crucial role in early
hematopoiesis—Stat5A and Stat5B doubly disrupted mice dis-
played a profound defect in competitive repopulation of hemato-
poiesis (Bunting et al., 2002; Snow et al., 2002). The commitment
of embryonic stem cells to hematopoietic cells is augmented by
a Stat5-mediated signal (Kyba et al., 2003). Stat5 also plays a role
in myeloid cell proliferation and differentiation (Ilaria et al., 1999).
Constitutive activation of Stat5 in human cord blood CD34+ cells
enhances their capacity to repopulate NOD/SCID mice and
promoteserythroiddifferentiation (Schuringaetal., 2004). Constitu-
tively active Stat5 promotes self-renewal, proliferation, and survival
of mouse hematopoietic stem cells (HSC) and induces a lethal
myeloproliferative disease (MPD) in mice (Kato et al., 2005).
Stat signals are downregulated by three well-characterized
mechanisms: dephosphorylation, nuclear export, and suppressor
of cytokine signaling (SOCS) feedback inhibition (Shuai, 2000;
Tanaka et al., 2005). SOCS proteins bind either activated Jak
proteins or cytokine receptors to inhibit Jak activity (Alexander
and Hilton, 2004). Several protein tyrosine phosphatases have
been reported to dephosphorylate either Jak and/or Stat proteins.
For example, Jak2 interacts with SHP-1 and may be dephos-
phorylated by SHP-1 (Jiao et al., 1996; Klingmuller et al., 1995).
Phospholipase C-b (PLC-b) is a small family of enzymes that
can produce diacylglycerol and IP3 downstream of heterotri-
meric G proteins (Rhee, 2001). As diacylglycerol can activate
protein kinase C (PKC), and IP3 can mobilize Ca
2+, PLC-b is
implicated in promoting cell proliferation. PLC-bdirectly interacts
with GTP-bound Ga subunits, leading to its catalytic activation.
The four isoforms of PLC-b (b1–b4) show different tissue expres-
sion specificity and heterotrimeric G protein regulation profiles.
PLC-b1 and PLC-b3 are expressed in a wide range of tissues
Figure 1. PLC-b3/ Mice Develop MPD, Lymphoma, and
Other Tumors
(A) Survival analysis.
(B) Summary of tumors developed in PLC-b3/ mice.
(C) Hematologic analysis of 10-month-old PLC-b3/ mice. Spleno-
megaly in PLC-b3/ mice (top left) was associated with effaced
splenic architecture (data not shown). Increased mature granulocytes
in PLC-b3/ mice were shown by blood smear (top right) and hema-
toxylin and eosin staining of lung and liver sections (bottom). Bars in
tissue sections indicate 30 mm.
(D) Flow cytometric analysis of nucleated cells in BM, spleen, and
peripheral blood leukocytes (PBL) from 10-month-old mice (n = 16).
Granulocytes (CD11b+/Gr-1+; percentages ± SD shown) were
increased in these organs of aged PLC-b3/ mice.
and cell types, while PLC-b2 and PLC-b4 are expressed
only in hematopoietic and neuronal tissues, respectively.
PLC-b2 and PLC-b3 can also be activated by bg subunits
of the Gai/o family of G proteins (Camps et al., 1992; Katz
et al., 1992; Lee et al., 1993). Consistent with their roles
in G protein-coupled receptor signaling, chemokine-
induced IP3 production, Ca
2+ signaling, and migration
are reduced inPLC-b2/ andPLC-b2/;PLC-b3/neutrophils
(Li et al., 2000) and T cells (Bach et al., 2007). However, little is
known about the role of these PLC-b isoforms in hematopoiesis
or tumorigenesis. Here we have studied the role of PLC-b3 in
these processes using PLC-b3/ mice.
RESULTS
PLC-b3-Deficient Mice Develop Various Tumors
Including MPD and Lymphoma
PLC-b3 deficiency led to a premature death in mice (Figure 1A).
Fifty percent (18 of 36 mice) of PLC-b3/ mice died within an
observation period of 16 months, in contrast with 100% survival
of wild-type (WT) mice. By the age of 16 months, most PLC-b3/
mice in this cohort exhibited splenomegaly (Figure 1B-C), the
incidence of which reached 89% when prematurely dead mice
with this abnormality were included. The enlarged spleens had
effaced architecture characterized by markedly increased
myeloid cells and some erythroid cells, indicative of extramedul-
lary hematopoiesis (data not shown). Livers and lungs also had
foci composed of myeloid cells (Figure 1C). Dramatic increases
in CD11b+Gr-1+ mature granulocytes in bone marrow (BM),
spleen, and peripheral blood from these mice were observed
(Figures 1C and 1D and see Tables S1 and S2 available with
this article online). Microbiological examinations showed no indi-
cations of bacterial infection in the diseased mice, and antibiotic
treatments did not affect the number of granulocytes (data not
shown). Therefore, these hematologic findings were consistent
with the diagnosis of MPD (Kogan et al., 2002), unlike myelodys-
plastic syndrome that is frequently associated with anemia.
During a 2 year observation period, three in another cohort of 16
PLC-b3/ mice with increased granulocytes developed anemia
(hematocrits of 11%, 16%, and 22%) with increased numbers of
blast cells in their BM (32%, 35%, and 45%, respectively). This
result suggests that the MPD can evolve to accelerated and
blast-crisis stages, similar to human chronic myelogenous
leukemia (CML) (Sawyers, 1999). Gross and histologic162 Cancer Cell 16, 161–171, August 4, 2009 ª2009 Elsevier Inc.
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PLC-b3 as a Potential Tumor Suppressorexaminations of a larger number (128 in total) of PLC-b3/ mice
revealed various tumors including lymphoma mostly with T cell
markers and carcinomas of skin and lung (Figures 1A and 1B
and Figure S1 and Table S3). Unlike PLC-b3/ mice, PLC-b2/
mice did not develop tumors or die prematurely (data not shown).
PLC-b3-Deficient Mice Exhibit Increased Numbers
of HSC and Myeloid Progenitors as well as Preferential
Granulocytic Differentiation
Aged PLC-b3/ mice with splenomegaly had increased
numbers of c-Kit+Sca-1+Lineage cells (KSL cells; enriched for
HSC), granulocyte-macrophage progenitors (GMP), and mega-
karyocyte-erythroid progenitors in both BM (Figure 2A and
Figure S2) and spleen (data not shown), compared to age-
matched WT mice. With regards to HSC subpopulations, PLC-
b3/ mice had 5-fold more CD34 KSL (enriched for long-term
repopulating HSC) and 3-fold more CD34+ KSL (enriched for
short-term repopulating HSC) cells (Figure 2A). Consistent with
the immunophenotypic data, PLC-b3/ BM cells and spleno-
cytes gave rise to greater numbers of myeloid colonies than WT
cells in methylcellulose medium (Figure S3A and data not shown).
Purified PLC-b3/ KSL and myeloid progenitors (CMP and
GMP) generated several-fold more granulocyte (CFU-G) colonies
of larger sizes than WT cells (Figures S3B–S3D), suggesting that
PLC-b3/ HSC and myeloid progenitors have an increased
predisposition to differentiate into granulocytes, which is consis-
tent with the MPD phenotype inPLC-b3/mice. Moreover,PLC-
b3/ BM and KSL cells were hypersensitive to cytokines (Fig-
ure S3E), a hallmark of human MPDs (Emanuel et al., 1991),
and formed macrophage (CFU-M) and granulocyte-macrophage
(CFU-GM) colonies in the absence of growth factors (Figure S3F),
a feature characteristic of transformed cells.
HSC-Enriched Populations Derived from PLC-b3/
Mice Exhibit Increased Proliferation and Survival
Given the above colony-formation data, blockade of differentia-
tion was ruled out as a contributing factor to the increase in
HSC-enriched populations inPLC-b3/mice. Thus the increase
in HSC-enriched populations could be accounted for by
increased proliferation, reduced cell death, altered migration,
or a combination of these factors. To dissect this point, we first
performed in vivo BrdU incorporation experiments in 10-
month-old mice. BrdU incorporation into KSL cells was greater
in PLC-b3/ mice (Figure 2B and Figure S4A), suggesting
increased proliferation in PLC-b3/ HSC-enriched populations.
Consistent with this result, PLC-b3/ CD34 KSL cells grew
faster and formed larger colonies than WT cells in the presence
of IL-3 or a cytokine cocktail (Figure 2C and data not shown). Cell
cycle analysis showed increased proportions of PLC-b3/
lineage cells in the S phase and reduced proportions of
PLC-b3/KSL cells in the G0 phase (Figures 2D–2E). Consistent
with the increased proliferation, mRNA levels of the cell cycle
inhibitor p19 were reduced, but those of cyclins A2 and B2
increased, inPLC-b3/KSL cells (Figure S5). We then measured
apoptotic cell death in KSL cells by annexin V staining. Apoptosis
was less abundant inPLC-b3/KSL cells (Figure 2F). In line with
this, expression of the antiapoptotic protein Bcl-2 was increased
in PLC-b3/ KSL cells (Figure 2G). Finally, homing capacity of
PLC-b3/ KSL cells was not altered (Figure S6). Therefore, we
conclude that the increase in HSC-enriched populations in
PLC-b3/ mice is due mainly to increased proliferation and
decreased apoptosis. The same mechanisms seem operative
inPLC-b3/GMP (Figures 2B and 2F and Figures S4B and S6B).
The MPD Is Transplantable with HSC-Enriched
Populations Derived from PLC-b3/ Mice
The MPD in PLC-b3/ mice was BM cell autonomous, as the
irradiated Ly5.1 mice that had received PLC-b3/ BM cells
developed MPD within 6–9 months (Table S4). The increased
proliferation and survival of PLC-b3/ KSL cells suggested
that HSC contain leukemic stem cells (Reya et al., 2001) that
cause MPD in PLC-b3/ mice. To test this hypothesis, purified
CD34 KSL, CD34+ KSL, CMP, and GMP from PLC-b3/
and WT mice were transferred into sublethally irradiated
Figure 2. Increases in KSL Cells and GMP in PLC-
b3/ Mice Are Due to Increased Proliferation and
Decreased Apoptosis
(A) BM cells from 10-month-old mice (n = 16) were sub-
jected to flow cytometric analysis of HSC and myeloid
progenitors (see Figure S2 as well). Results shown are
representative of at least four measurements.
(B) In vivo BrdU incorporation into KSL and GMP cells in
10-month-old mice (n = 4).
(C) CD34 KSL cells from 10-month-old mice (n = 4) were
sorted into 96-well plates containing IL-3, SCF, IL-11,
Flt3L, and TPO, and cultured for 4 days. The inset shows
representative colonies generated at the bottom of well
on day 4. Representative of four independent experi-
ments.
(D and E) Cell cycle analysis of propidium iodide-stained
Lin cells (D) and Hoechst 33342 and Pyronin Y-stained
(E) KSL cells from 10-month-old mice (n = 4).
(F) Flow cytometric analysis of annexin V+ apoptotic cells
in KSL and GMP cells from 10-month-old mice (n = 4).
Results in (A)–(F) represent mean ± SD. *p < 0.05 versus
WT cells by Student’s t test.
(G) Flow cytometric analysis for Bcl-2 expression in Lin
cells from 10-month-old mice (n = 2).Cancer Cell 16, 161–171, August 4, 2009 ª2009 Elsevier Inc. 163
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PLC-b3 as a Potential Tumor SuppressorRag2/-Ly5.1 mice. Only PLC-b3/ CD34 KSL cells, but not
other cell populations, gave rise to myeloid hyperplasia in recip-
ient mice within only 2 months (Table S4). These results suggest
that the leukemic stem cells responsible for the development of
MPD in PLC-b3/ mice are present in CD34 KSL cells.
Increased Stat5 Activity Is Critical for Increased
Proliferative,Myeloid-Differentiative, andMPD-Causing
Capabilities of PLC-b3/ KSL Cells
We next analyzed the signaling pathways accountable for the
increased proliferation, survival, and myeloid differentiation of
PLC-b3/ KSL cells. Unlike BCR-ABL-induced CML (Sawyers
et al., 1995; Skorski et al., 1997), activities of Ras, ERK, and
Akt were comparable in WT and PLC-b3/ KSL and mouse
embryonic fibroblasts (MEFs) (Figure S7A and data not shown).
Importantly, however, Stat5 Tyr-694 phosphorylation was
constitutively increased and further induced after stimulation
with IL-3 or a cytokine cocktail in PLC-b3/ KSL cells (Figure 3A
and Figure S7B) and, compared to WT cells, more frequent and
extensive nuclear localization of phospho-Stat5 was observed in
PLC-b3/ KSL cells (Figure 3B). In contrast, Stat3 phosphoryla-
tion was comparable in PLC-b3/ and WT cells (Figure 3A and
Figure S7B). Lymphomas and a skin carcinoma from PLC-b3/
mice also exhibited increased phosphorylation of Stat5, but not
Stat3 (Figure 6C and Figure S7C and data not shown). Consis-
tent with Stat5 activation, mRNA expression of Stat5 target
genes, e.g., CIS (Matsumoto et al., 1997), pim-1 (Lilly and Kraft,
1997; Nosaka et al., 1999), and oncostatin M (Yoshimura et al.,
1996), was increased in PLC-b3/ cells (Figure 3C).
To directly test the functional relevance of increased Stat5
activation, we introduced dominant-negative (DN) Stat5 into
KSL cells, using a bicistronic retrovirus encoding DN Stat5 and
green fluorescent protein (GFP). DN Stat5 induced a reduction
in mRNA expression of CIS, pim-1, and oncostatin M (Figure 3C)
as expected. DN Stat5 suppressed in vitro expansion of GFP-ex-
pressing PLC-b3/ KSL cells (designated as KO/DNStat5 cells)
(Figure 3D), suggesting that the increased proliferation/survival
depends on the increased Stat5 activity in PLC-b3/ HSC-
enriched cells. Colony-forming assays on KO/DNStat5 cells
showed a drastic reduction of granulocyte (CFU-G and CFU-
GM) colonies compared to KO/vec cells harboring an empty
vector (Figure 3E). By contrast, DN Stat3 had little effect on the
proliferation and colony-forming abilities of PLC-b3/ and WT
cells. Furthermore, the lethally irradiated Ly5.1+ mice that had
received KO/DNStat5 cells had drastically fewer donor (GFP+)-
derived blood cells (Figure 3F) and KSL cells (Table S5) than
the mice that had received KO/vec cells, indicating that Stat5
is required for engraftment or cell proliferation/survival of the
Figure 3. Stat5 Activation Is Required for the
Increased Proliferation and Myeloid Differentiation of
PLC-b3/ KSL Cells
(A and B) Phospho-Stat5 levels were constitutively () higher
in PLC-b3/ KSL cells and further increased upon stimulation
for 5 min with a cytokine cocktail of IL-3, SCF, IL-11, Flt3L, and
TPO (+), as shown by flow cytometric analysis (A) and confocal
microscopy (B) with anti-p-Stat5 (Tyr694). Nuclei were stained
with DAPI (blue). A bar indicates 10 mm. The patterns of phos-
pho-Stat5 staining in confocal microscopy were categorized
into four (I–IV) and their distributions in cytokines-stimulated
KSL cells (200 cells counted) from 8- to 10-month-old mice
(n = 8) are shown. Representative of four (A) and two (B) inde-
pendent experiments.
(C) RT-PCR analysis of mRNA expression of Stat5 target
genes, CIS, pim-1, and oncostain M in KSL cells from 10-
month-old mice (n = 4). Numbers of PCR cycles performed
are indicated. GAPDH mRNA is a housekeeping gene
control.
(D) CD34 KSL cells were transduced with a bicistronic retro-
viral vector encoding DN Stat5 (DN5) or DN Stat3 (DN3).
GFP+ transduced cells were cultured in the presence of
IL-3, SCF, IL-11, Flt3L, and TPO. Representative of three
independent experiments. Results in (B) and (D) represent
mean ± SD.
(E) Transduced cells were cultured in methylcellulose
medium containing SCF, IL-3, IL-6, and EPO. B, G, M, GM,
and Mix represent BFU-E, CFU-G, CFU-M, CFU-GM, and
CFU-Mix, respectively.
(F and G) PLC-b3/ CD34 KSL cells transduced with DN
Stat5 or empty vector were adoptively transferred to lethally
irradiated C57BL/6-Ly5.1 mice. Two and four months later,
peripheral blood was analyzed by flow cytometry for enumer-
ation of GFP+ cells (F) and donor-derived CD11b+ cells (G).
See Table S5 as well. *p < 0.05 by Student’s t test.164 Cancer Cell 16, 161–171, August 4, 2009 ª2009 Elsevier Inc.
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PLC-b3 as a Potential Tumor Suppressortransferred cells as shown by Bunting et al. (2002). Among the
GFP+ donor cells, the former mice had much fewer CD11b+ cells
than the latter mice, whereas GFP cells in mice that had
received KO/vec or KO/DNStat5 cells showed high proportions
of CD11b+ cells similar to those among GFP+ cells in mice that
had received KO/vec cells (Figure 3G). These results support
the notion that the increased Stat5 activity is responsible for
the myeloid-differentiative activities of PLC-b3/ HSC-enriched
populations. There were increases in myeloid cell percentage
from 2 to 4 months after transfer in mice that received both
control (vec) and DN Stat5-tranduced cells, suggesting a begin-
ning of MPD development despite the DN Stat5 expression or
retroviral inactivation or escape mechanism.
PLC-b3 Suppresses the Growth of Hematopoietic Cells
through Its C-Terminal Fragment
IL-3-dependent mouse Ba/F3 cells have been extensively used
to investigate Stat5-related signaling events (Warmuth et al.,
2007). Expression of PLC-b3 at 2- to 5-fold higher levels over
the endogenous level inhibited IL-3-dependent proliferation of
Ba/F3 cells, accompanied by reduced Stat5 phosphorylation
(Figures 4B and 4C). Next we determined the structural require-
ments for growth suppression. Importantly, the C-terminal frag-
ment (CT) corresponding to residues 809–1234 retained as
strong a growth-suppressive activity as full-length PLC-b3 (Fig-
ure 4B). However, the catalytic domain of PLC-b3 was not
required for suppressive activity, as two catalytically inactive
mutants, E362G and del, showed a slightly stronger, if any,
growth-suppressive activity (Figure 4B), consistent with the
assumption that the PLC catalytic activity enhances cellular
growth. The PH domain had no effect on cellular growth. The
growth-suppressive function of CT was confirmed in vivo:
PLC-b3/ KSL cells transduced with CT failed to cause MPD
in recipient mice (Figure S8B). KSL cells recovered from such
recipient mice showed slower in vitro growth with lower levels
of Stat5 phosphorylation than KSL cells from mice that had
received empty vector-transduced PLC-b3/KSL cells (Figures
S8C and S8D).
Multimolecular Interactions Involve PLC-b3, Stat5,
and SHP-1
We found physical interactions between PLC-b3 and Stat5.
Thus, anti-PLC-b3 antibody coimmunoprecipitated Stat5 from
Ba/F3 cell lysates (Figure 4D). Low-level coimmunoprecipitation
before stimulation was followed by a transient increase with
a peak at 1–3 min upon IL-3 stimulation. Reciprocally, PLC-b3
was coimmunoprecipitated with anti-Stat5 antibody (Figure 4D).
IL-3-inducible interactions between PLC-b3 and Stat5 were also
shown in mouse splenocytes (Figure S9A). Consistent with these
biochemical data, confocal imaging analysis showed colocaliza-
tion of PLC-b3 with phospho-Stat5 in the cytoplasm of IL-3-stim-
ulated Ba/F3 cells (Figure S9B). By contrast, Stat3 was not coim-
munoprecipitated with PLC-b3 (data not shown). Given the
potential role of SHP-1 in dephosphorylating Stat5 and inhibiting
IL-3-dependent cell growth (Paling and Welham, 2002), we
examined whether PLC-b3 interacts with SHP-1. Indeed, coim-
munoprecipitation was observed between PLC-b3 and SHP-1
in Ba/F3 and spleen cells (Figure 4D and Figure S9A), but not
between PLC-b3 and other phosphatases such as SHP-2,
PP2A, and PTP-1B, despite their robust expression in Ba/F3
cells (data not shown). PLC-b3/SHP-1 interactions were largely
constitutive, but increased by 30%–150% at 10 min stimulation
Figure 4. Functional Multimolecular SPS
Complexes Contain PLC-b3, Stat5, and SHP-1
(A) Scheme for a panel of PLC-b3 retroviral constructs.
(B) Growth-suppressive function of various PLC-b3
constructs. Ba/F3 cells were transduced with a bicis-
tronic retroviral vector expressing GFP alone (vector)
or GFP and either full-length (FL) PLC-b3 or its frag-
ment. Growth responses to the indicated concentra-
tions of IL-3 are shown. S1105G and CTD showed
almost the same inhibitory effects as CT (data not
shown). Similar results were obtained in multiples
experiments (at least five times using FL and CT
constructs).
(C) FL- and vector-transduced Ba/F3 cells were lysed
and directly analyzed by immunoblotting.
(D) Lysates of IL-3-stimulated nontransduced Ba/F3
cells were immunoprecipitated (IP) and followed by
immunoblotting (IB) with the indicated antibodies.
(E) Splenocytes from PLC-b3/, mev/mev, polyI:C-
treated Stat5fl/fl;Mx1-cre, and control (WT) mice were
analyzed by immunoprecipitation and immunoblot-
ting.
(F) PLC-b3 CT facilitated SHP-1-mediated dephos-
phorylation of phospho-Stat5 in vitro.
(G) PLC-b3 and SHP-1 synergistically inhibited IL-3-
dependent growth of Ba/F3 cells. *p < 0.05 and **p <
0.01 versus vector control by Student’s t test. Results
in (B) and (G) represent mean ± SD.Cancer Cell 16, 161–171, August 4, 2009 ª2009 Elsevier Inc. 165
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PLC-b3 as a Potential Tumor Suppressorwith IL-3 (Figure 4D). Stat5 also interacted with SHP-1 and this
interaction slightly increased at 1 and 10 min stimulation with
IL-3 (Figure 4D and Figure S9A). The ability of PLC-b3 CT to
interact with SHP-1 and Stat5 were confirmed by in vitro GST
fusion protein pull-down assays (Figure S10).
Pairwise interactions among PLC-b3, Stat5, and SHP-1 raised
the possibility that these molecules are present in the same
multimolecular complex. To test this hypothesis, we performed
a series of immunodepletion/immunoprecipitation experiments.
Briefly, depletion of one of these three molecules from Ba/F3
lysates abrogated or drastically reduced the interaction between
the other two molecules (Figure S11). As these results indicate
the presence of a multimolecular complex, we propose to call
it the SPS complex, which includes SHP-1, PLC-b3, and Stat5
as components. Pairwise interactions among PLC-b3, SHP-1,
and Stat5 were modestly induced upon IL-3 stimulation in non-
transduced Ba/F cells and splenocytes from normal mice
(Figure 4D and Figure S9A). IL-3-mediated inducibility of interac-
tions among these molecules became more remarkable in Ba/F3
cells overexpressing PLC-b3 (Figure S9C). These results
suggest that pairwise interactions among the three proteins,
particularly PLC-b3/Stat5 interactions, can be inducible by IL-3
stimulation. As immunodepletion of one component from IL-3-
stimulated, PLC-b3-overexpressing Ba/F3 cells completely or
near completely abrogated interactions between the other two
components (Figure S11), large proportions of these three mole-
cules were interpreted to reside in SPS complexes upon IL-3
stimulation. Furthermore, PLC-b3 deficiency almost abrogated
the SHP-1/Stat5 interaction and the motheaten viable (mev/mev)
mutation in SHP-1 (Tsui et al., 1993) drastically reduced the PLC-
b3/Stat5 interaction (Figure 4E). These results suggest that
formation of stable SPS complexes require PLC-b3 and normal
SHP-1 proteins. By contrast, 80% reduction in Stat5 expres-
sion did not affect the PLC-b3/SHP-1 interaction (Figure 4E),
together with our observation of the direct interaction between
PLC-b3 and SHP-1 (Figure S10F), suggesting that Stat5 may
not be required for the initial assembly of SPS complexes. These
results suggest the dynamic nature of the SPS complex, in which
PLC-b3 and SHP-1 function as a limiting factor in its assembly.
PLC-b3 Enhances SHP-1-Mediated Dephosphorylation
of Stat5
Functional relationship among the components of the SPS
complex was assessed in an in vitro phosphatase assay using
recombinant SHP-1 and PLC-b3 CT (GST-PLC-b3 CT). The
substrate used in this assay was phospho-Stat5 immunoprecip-
itated from pervanadate-stimulated Daudi cells, which ex-
pressed low levels of PLC-b3 (see Figure 7A). Phospho-Stat5
levels were modestly reduced by incubation with WT, but not
catalytically inactive D419A, SHP-1 (Figure 4F, lanes 2 and 3),
providing the direct evidence that SHP-1 can dephosphorylate
phospho-Stat5. More importantly, incubation of phospho-Stat5
with GST-PLC-b3 CT plus WT (but not D419A mutant) SHP-1
drastically reduced phospho-Stat5 levels (Figure 4F, lane 5).
Incubation of phospho-Stat5 with GST-PLC-b3 CT alone slightly
reduced phosphorylation levels, suggesting that the catalytic
activity of the endogenous, Stat5-associated SHP-1 was
enhanced with GST-PLC-b3 CT. Indeed, probing the same blot
with anti-SHP-1 confirmed the presence of endogenous SHP-1166 Cancer Cell 16, 161–171, August 4, 2009 ª2009 Elsevier Inc.in Stat5 immunoprecipitates. We next tested the functional rele-
vance of the SPS complex in the cellular context. Coexpression
of PLC-b3 and SHP-1 had a stronger inhibitory effect on IL-3-
induced Ba/F3 cell proliferation, compared to those of PLC-b3
or SHP-1 alone (Figure 4G). These results suggest that the
SPS complex is functional and that PLC-b3 present in the SPS
complex augments the phosphatase activity of SHP-1 toward
phospho-Stat5.
PLC-b3 CT Cannot Suppress the Proliferative, Myeloid-
Differentiative, and MPD-Causing Capabilities of HSC
Derived from Motheaten Viable Mice
Given the probable role of the SPS complex in antagonizing
Stat5 activation, we investigated whether the apparent MPD in
mev/mev mice (Figure 5A) has a similar pathogenic mechanism
as that in PLC-b3/ mice. Indeed, increased numbers of KSL
and GMP cells were present in the BM of mev/mev mice (Fig-
ure 5B). CD34 KSL cells from mev/mev mice grew faster
in vitro with higher levels of Stat5 phosphorylation than WT cells
(Figures 5C and 5D) and their in vitro growth was inhibited by DN
Stat5 (Figure 5E). The MPD in mev/mev mice was BM cell auton-
omous (Figure S12) and mev/mev CD34 KSL cells transduced
with DN Stat5 failed to develop MPD in recipient mice (Figure 5F).
Therefore, we concluded that constitutive Stat5 activation is
a shared mechanism for MPD development in PLC-b3/ and
mev/mev mice. Interestingly, in vitro growth of mev/mev CD34
KSL cells was only marginally affected by PLC-b3 CT (Figure 5E)
and transduction of mev/mev CD34 KSL cells with full-length
PLC-b3 or PLC-b3 CT did not prevent MPD development in
recipient mice (Figure 5F), similar to nontransduced (GFP) cells
(Figure 5G). By contrast, mev/mev CD34 KSL cells transduced
with WT SHP-1 did not cause MPD in recipient mice. Together
with the reduced PLC-b3/Stat5 interaction in mev/mev cells
(Figure 4E), these results suggest that aberrant SHP-1 proteins
encoded by mev/mev (Shultz et al., 1993) cannot use the adaptor
function of PLC-b3 to suppress Stat5 phosphorylation.
PLC-b3 Haploinsufficiency Cooperates with c-Myc
to Transform Fibroblasts and Lymphocytes
To further analyze the transforming ability of PLC-b3-deficient
cells, we transfected PLC-b3/ MEFs with V12 H-ras or c-myc.
Unlike active H-ras, which induced senescence in WT and PLC-
b3/MEFs (data not shown), c-myc induced in vitro transforma-
tion in PLC-b3+/ and PLC-b3/MEFs (Figure 6A). In light of this
observation, we investigated whether PLC-b3 deficiency can
cooperate with c-myc to induce in vivo tumor formation, by
crossing PLC-b3/ mice with Em-myc transgenic mice. As re-
ported previously (Adams et al., 1985), Em-myc transgenic
mice developed B cell-lineage lymphomas with a long latency.
Lymphoma formation in Em-myc transgenic mice with heterozy-
gous PLC-b3+/ loci was dramatically accelerated (median
survival: 100 days in Em-myc;PLC-b3+/ mice versus >365 in
Em-myc;PLC-b3+/+ mice) (Figure 6B). These Em-myc;PLC-b3+/
lymphomas expressed a pre-B cell phenotype of B220+ IgM
CD43 (data not shown). These and PLC-b3/ lymphomas
showed higher levels of Stat5 phosphorylation than normal
lymphoid tissues (Figure 6C). Importantly, all analyzed PLC-
b3/ lymphomas showed as high c-Myc expression as did
Em-myc;PLC-b3+/ lymphomas. On the other hand, the
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PLC-b3 as a Potential Tumor SuppressorFigure 5. MPD-Causing Ability of HSC-
Enriched Cells Derived from Motheaten
Viable Mice Depend on Stat5
(A) Flow cytometric analysis of nucleated cells in
BM, spleen, and peripheral blood (PBL) of 6- to
8-week-old mice (n = 6). Granulocyte percentages
are shown.
(B) Flow cytometric analysis of KSL and GMP in BM
(n = 6). *p < 0.05 versus WT cells.
(C) CD34 KSL cells from 6- to 8-week-old mice
(n = 4) were sorted and cultured in IL-3, SCF,
IL-11, Flt3L, and TPO. Representative of three
independent experiments.
(D) Flow cytometric analysis of phospho-Stat5
levels (n = 4).
(E)mev/mev CD34KSL cells were transduced with
a bicistronic retroviral vector expressing DN Stat5,
PLC-b3 CT, or empty vector (vec). Growth of GFP+
cells was monitored. *p < 0.05 versus empty vector
cells. Results in (B)–(E) represent mean ± SD.
(F and G) mev/mev CD34 KSL cells were trans-
duced with the indicated constructs and adoptively
transferred to lethally irradiated mice. Two months
later, peripheral blood was analyzed by flow cy-
tometry for enumeration of CD11b+ cells in GFP+
donor-derived cells. Similar results were observed
4 months after transfer (data not shown). *p < 0.05;
ns, not significant.expression of PLC-b3 protein in Em-myc;PLC-b3+/ lymphomas
was drastically reduced compared to normal lymphoid tissues
(Figure 6C). As extensive RT-PCR analyses covering all exon
sequences of PLC-b3 mRNA gave the same levels (Figure S13)
in WT spleens and two Em-myc;PLC-b3+/ lymphomas (samples
1 and 2 in Figure 6C) and no mutations were found in the PLC-b3
exons (data not shown), the very low expression of PLC-b3
protein in these lymphomas seemed due to abnormal posttran-
scriptional regulation of PLC-b3 mRNA: stability of the PLC-b3
protein might be low. Alternatively, translation of the PLC-b3 pro-
tein might be abnormal and inefficient in Em-myc;PLC-b3+/
lymphomas. Another possibility is somatic-inactivating point
mutations in other cases of Em-myc;PLC-b3+/ lymphomas.
However, PLC-b3 protein expression in PLC-b3+/ splenocytes
is reduced by about 50% as expected (data not shown), which
is consistent with the fact that PLC-b3+/ mice did not show
any abnormal phenotypes. Retroviral expression of DN Stat5
or PLC-b3 CT in Em-myc;PLC-b3+/ lymphoma cells suppressed
their in vitro growth and colony formation (Figures 6D and 6E).
These results indicate that PLC-b3 haploinsufficiency cooper-
ates with c-Myc to transform fibroblasts and lymphocytes.
Translocations of c-myc to immunoglobulin or other gene loci
and thus abnormal expression of c-myc are causally linked to
Burkitt’s lymphoma (Boxer and Dang, 2001). Interestingly, two
of six Burkitt’s lymphoma cell lines tested, i.e., Daudi and Raji,
exhibited very low levels (5%–10% that in Ba/F3 cells) of PLC-
b3 protein and they had higher basal levels of STAT5 phosphor-
ylation than the other Burkitt’s cells with high PLC-b3 expression
(Figure 7A). Overexpression of PLC-b3 CT in Daudi and Raji cells
blocked their growth (Figure 7B and data not shown) and
reduced STAT5 phosphorylation (Figure 7C). Expression of DN
STAT5 also blocked the growth of these Burkitt’s lymphoma
cells (Figure 7D and data not shown), but not that of Ramos cells
expressing high levels of PLC-b3 (data not shown). These resultstogether with observations on PLC-b3/ and Em-myc;PLC-b3+/
lymphomas are consistent with the notion that reduced or abro-
gated expression of PLC-b3 may cooperate with active c-Myc to
induce lymphoma in mice and humans. In addition to these
lymphoid tumor cells, overexpression of full-length PLC-b3 or
CT in GM-CSF-dependent TF-1 erythroleukemia cells sup-
pressed GM-CSF-dependent cell growth associated with re-
pressed STAT5 phosphorylation (Figures 7E and 7F); on the
other hand, knockdown (to a level of 20%–30% that in Ba/F3
cells) of PLC-b3 expression using lentivirus-mediated RNA inter-
ference rendered TF-1 cell growth independent of GM-CSF and
associated with increased STAT5 phosphorylation (Figures 7G
and 7H). Similarly, overexpression of full-length PLC-b3 or CT
suppressed the growth factor-dependent proliferation and/or
survival of other human leukemic cell lines such as MEC2 and
HL-60 (data not shown). Eleven percent of chronic lymphocytic
leukemia (CLL) samples showed low levels of PLC-b3 expres-
sion with high phospho-STAT5 levels (Figure 7I and data not
shown). The results collectively suggest that reduced expression
of PLC-b3 and thus the loss of the SHP-1-mediated Stat5
dephosphorylation mechanism cooperates with active c-myc
(or an unknown oncogene) to induce lymphoid and myeloid
malignancies in mice and humans.
DISCUSSION
This study demonstrates an adaptor function of PLC-b3 that
negatively regulates proliferative, survival, and myeloid-differen-
tiative capabilities of HSC-enriched cell populations. PLC-b3
augments SHP-1-mediated deactivation of Stat5 activity (Fig-
ure 8). Loss of this regulation seems to lead to MPD develop-
ment in aged PLC-b3/ mice. Long latency suggests that an
additional transforming event is required for conversion of
PLC-b3/ HSC/progenitor cells to malignant cells. Importantly,Cancer Cell 16, 161–171, August 4, 2009 ª2009 Elsevier Inc. 167
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Cooperative transformation by active c-myc and PLC-b3 defi-
ciency seems to underlie lymphomas in PLC-b3/ and Em-myc;
PLC-b3+/ mice and a subset of human Burkitt’s lymphoma.
However, c-myc expression was not increased in PLC-b3/
KSL cells (data not shown), suggesting that an oncogene other
than c-myc seems responsible for MPD development.
All the tested MPD, lymphoma, and other tumor cells derived
from PLC-b3/ mice had high phospho-Stat5 levels, and DN
Stat5 suppressed the growth of PLC-b3/ HSC and lymphoma
cells, suggesting that Stat5 activation is part of the necessary
transforming processes in these malignancies. Stat5 is fre-
quently activated in leukemia (Benekli et al., 2003; Frohling
et al., 2005). Stat5 activation was shown to be essential for
MPD or myeloid leukemia induced by the activated oncogenes,
such as TEL/JAK2 (Schwaller et al., 2000), TEL/PDGFRB (Cain
et al., 2007), and FLT3 ITD (Choudhary et al., 2007), and by defi-
ciencies of SHIP and Lyn/Hck (Xiao et al., 2008). An activating
mutation (V617F) in JAK2 was found in human MPDs (Baxter
et al., 2005; James et al., 2005; Kralovics et al., 2005; Levine
et al., 2005). However, Jak2 cDNAs cloned from PLC-b3/
KSL cells had the WT sequence around the V617 residue (data
not shown). Therefore, it will be interesting to study what kinase
activates Stat5 in PLC-b3/ mice.
We provide the direct evidence that SHP-1 can dephosphory-
late Stat5 to dampen Stat5 activity. This function is lost in mev/
mev mice; this deficiency underlies the MPD in these mice, as
Figure 6. PLC-b3 Deficiency Cooperates with c-Myc to
Transform Mouse Fibroblasts and Lymphocytes
(A) MEFs from WT, PLC-b3+/, and PLC-b3/ mice (n = 8 each) were
transfected with c-myc and subjected to semisolid colony-forming
assays. Similar results were observed in another experiment.
(B) Survival curves for the indicated mice.
(C) Immunoblot analysis of PLC-b3/ (five independent tumors) and
Em-myc;PLC-b3+/ (three tumors) lymphomas and normal lymphoid
tissues. WT samples 1 and 2–4 represent thymus and spleens,
respectively, from WT mice.
(D and E) Em-myc;PLC-b3+/ lymphoma cells were cultured and retro-
virally transduced with the indicated genes. Their in vitro growth (D)
and colony numbers in semisolid medium (E) were quantified after
sorting GFP+ cells. Results represent two independent experiments.
Results in (A), (D), and (E) represent mean ± SD.
transduction with DN Stat5 inhibited in vitro growth of
mev/mev CD34 KSL cells and MPD development in
recipient mice. Transduction ofmev/mev CD34KSL cells
with SHP-1, but not PLC-b3 CT, blocked their MPD-
causing capability. These results demonstrate that aber-
rant SHP-1 proteins generated by the mev locus cannot
suppress Stat5 phosphorylation. This could be due to
the loss of PLC-b3/Stat5 interactions, low enzymatic
activity of the mutant SHP-1 proteins, or both.
We have provided biochemical evidence for physical
interactions among PLC-b3, Stat5, and SHP-1. Pairwise
interactions were modestly enhanced upon IL-3 stimula-
tion, but they were much more strongly induced in Ba/F3
cells overexpressing PLC-b3, suggesting the dynamic
nature of complex formation that is under the control of
PLC-b3 levels and IL-3 stimulation. However, the struc-
ture and function of this complex remained to be defined. Our
in vitro phosphatase assays showed that SHP-1 can dephos-
phorylate phospho-Stat5 on Tyr-694 to deactivate Stat5 and
that PLC-b3 CT augments this dephosphorylation reaction.
Therefore, we hypothesize that SPS complex formation en-
hances the activity of SHP-1 to deactivate Stat5 to prevent
unchecked Stat5 activation. Further, the dysregulation of this
mechanism at the level of HSC may lead to the development of
MPD. It is tempting to speculate that similar dysregulation in other
hematopoietic or non-hematopoietic cells may also contribute to
tumorigenic processes of various malignancies.
PLC-b3 CT can specifically interact with Stat5 and SHP-1. The
corresponding CT of turkey PLC-b forms a coiled-coil structure
that dimerizes along its long axis, a structure for interactions
with GTP-bound Gaq (Singer et al., 2002). This part of PLC-b3
has low sequence similarity (30% identity) to the corresponding
region of PLC-b2. Consistent with this and biological differences
between PLC-b3/ and PLC-b2/ mice, PLC-b2 did not coim-
munoprecipitate with Stat5 or SHP-1 (data not shown). Muta-
tions of Ser-1105 (PKC phosphorylation site) or the C-terminal
residues (PDZ domain-binding site) did not affect the growth-
suppressive activity. These results indicate that PLC-b3 CT
contains a determinant responsible for growth suppression
with interaction sites for Stat5 and SHP-1.
Information in the public domain, e.g., the Cancer Genome
Anatomy Project website (http://cgap.nci.nih.gov/Chromosomes/),
indicates reduced or abrogated expression of PLC-b3 in human168 Cancer Cell 16, 161–171, August 4, 2009 ª2009 Elsevier Inc.
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ations in acute lymphocytic leukemia (ALL) demonstrated that
a small number of ALL patients have deletions of the region of
chromosome 11 including the PLC-b3 gene (Mullighan et al.,
2007). Furthermore, the Oncomine database (Rhodes et al.,
2004) shows that reduced expression of PLC-b3 mRNA is asso-
ciated with higher grades of bladder carcinoma (p = 4.23 107).
We also found loss or reduced PLC-b3 expression in human
tumor cell lines (Figure 7I and data not shown). Therefore,
reduced or abrogated expression of PLC-b3 may play a role in
the tumorigenic process of human malignancies.
Regulation of PLC-b3 expression has not been well studied.
Therefore, it is not clear how PLC-b3 expression is reduced or
abrogated in tumors. One obvious possibility is deletions of the
chromosomal region encompassing the PLC-b3 gene, as shown
in the aforementioned ALL cases. Another possible mechanism
is DNA methylation of the gene promoter. Indeed, treatment
with decitabine, an inhibitor of the DNA methyltransferase
activity, restored PLC-b3 expression in Daudi cells (data not
shown). There might be other unknown mechanisms for reduced
expression. However, simple mutations or gene fusions do not
seem to be involved in reduced or abrogated expression of
PLC-b3, as such mutations in the human PLC-b3 gene were
not found in 136 tumor samples (COSMIC website, http://
www.sanger.ac.uk/genetics/CGP/cosmic/). However, this issue
warrants further investigation.
EXPERIMENTAL PROCEDURES
Mice and MPD
PLC-b3/ and PLC-b2/ mice were described previously (Li et al., 2000).
Mev, C57BL/6-Ly5.1, and the Rag2/-Ly5.1 mice were purchased from the
Jackson Laboratory and Taconic, respectively. Stat5 floxed mice (Cui et al.,
2004) with Mx1-cre will be described elsewhere (A.K. and L.H., unpublished
data). For the definition of MPD, we followed the criteria adopted by the Mouse
Models of Human Cancers Consortium (Kogan et al., 2002) and by Passegue
et al. (2004). The Animal Care and Use Committee of the La Jolla Institute for
Allergy and Immunology approved all mouse experiments.
Figure 8. Proposed Mechanism for PLC-b3-Mediated Inhibition of
Stat5 Overactivation
Following cytokine stimulation, the Jak-Stat pathway is activated, leading to
activation of Stat target genes. PLC-b3/ SHP-1 complexes recruit phosphory-
lated Stat5 to its C-terminal domain to form SPS complexes. PLC-b3 in the
complexes augments the capability of SHP-1 of dephosphorylating Stat5
and inhibiting its nuclear translocation. At this point we do not know whether
monomeric or dimeric phosphorylated Stat5 is recruited.
Figure 7. Growth Regulation of Burkitt’s
Lymphoma and Erythroleukemia Cells by
PLC-b3
(A) Daudi and Raji cells, but not other Burkitt’s
lymphoma cells, express very low levels of PLC-b3
(as shown by immunoblotting) and high levels of phos-
pho-STAT5 (as shown by flow cytometry).
(B–D) Daudi cells were retrovirally transduced with the
indicated genes. GFP+ transduced cells were FACS
sorted and enumerated (B and D). (C) Phospho-
STAT5 levels in the transduced Daudi cells were
measured by flow cytometry.
(E and F) TF-1 cells were transduced with full-length
(FL) PLC-b3 or CT, and then GFP+ cells were cultured
in the presence of GM-CSF. The inset in (E) shows
expression of PLC-b3 and (F) shows phospho-
STAT5 MFI levels.
(G and H) TF-1 cells were lentivirally transduced with
short hairpin RNA (shRNA) constructs targeting the
human PLC-b3 gene. The inset shows that sh1 and
sh2, but not sh3, constructs efficiently inhibited
expression of PLC-b3 protein. (H) Transduced TF-1
cells were stimulated by GM-CSF for 3 min before
flow cytometric measurement of phospho-STAT5.
(I) Immunoblot analysis of human CLL. Results in (A),
(B), and (D)–(H) represent mean ± SD.Cancer Cell 16, 161–171, August 4, 2009 ª2009 Elsevier Inc. 169
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See the Supplemental Data for the identification and purification of HSC. For
proliferation assays, KSL or CD34 KSL cells were sorted into a 96 well round
bottom plate (one cell per well) in 200 ml of IMDM containing 5% FBS, 50 mM 2-
mercaptoethanol, and either IL-3 (10 ng/ml) alone or a cocktail of stem cell
factor (SCF), IL-3, Flt3L, thrombopoietin (TPO), and IL-11, and incubated at
37C for the indicated periods. The number of cells per well were visually
determined under an inverted microscope. In some experiments, 50 or 150
CD34 KSL cells were sorted per well and a cocktail of SCF, Flt3L, and
IL-11 was added. For BrdU incorporation, cell cycle analysis, and analysis of
phosphorylated signaling molecules in HSC, see the Supplemental Data.
Retroviral Transduction
Recombinant retroviruses were produced as previously described (Kato et al.,
2005). Sorted CD34 KSL cells (150 cells/well) were incubated in a-MEM sup-
plemented with 1% FBS, SCF, and human TPO for 24 hr, and then transduced
with a retrovirus vector (pMX-GFP-DN Stat5 or DN Stat3; pMIG-SHP-1 or
pMIG-PLC-b3 or -CT) in the presence of protamine sulfate (10 mg/ml) and
recombinant fibronectin fragment (1 mg/ml) for 24 hr. Transduced cells were
further subjected to liquid (in the presence of SCF, Flt-3L, and IL-11) or
semi-solid cultures (MethoCult M3434 from StemCell Technologies). In these
experiments, transduction efficiency was80% as judged by GFP expression
by epifluorescence microscopy.
Transplantation of Hematopoietic Cells
BM cells (23 106 cells in 400 ml PBS) were injected into the tail vein of lethally
(960 rad) irradiated recipient mice (C57BL/6-Ly5.1; 8–10 weeks old). For
transplantation of HSC and progenitors, FACS-sorted CD34 KSL, CD34+
KSL, CMP, and GMP were injected into sublethally irradiated (450 rad)
Rag2/-Ly5.1 recipient mice. We also transplanted retrovirally transduced
HSCs into lethally irradiated C57BL/6-Ly5.1 mice together with 2.5 3 105
Sca-1-depleted C57BL/6-Ly5.1 helper BM cells.
Transduction, Coimmunoprecipitation, and Immunodepletion
of Ba/F3 Cells
Ba/F3 cells were cultured in IL-3-containing medium and transduced with
a retrovirus vector (pMIG-myc-PLC-b3 WT or mutants). Forty-eight hours later,
transduced GFP+ cells were FACS-sorted into a 96 well plate at a density of 50
cells per well and cultured in the presence of IL-3. For coimmunoprecipitation,
transduced cells deprived of IL-3 were stimulated with 10 ng/ml of IL-3, and
cell lysates were immunoprecipitated with anti-Stat5 (C-17), anti-PLC-b3
(C-20) (or anti-myc), or anti-SHP-1 (C-19) antibodies (all from Santa Cruz
Biotechnology). For immunodepletion, cell lysates were precipitated with
anti-Stat5, anti-PLC-b3, or anti-SHP-1 antibodies, and supernatants were
collected for coimmunoprecipitation.
In Vitro Phosphatase Assay
In vitro phosphatase assay was performed essentially as described (Nakahira
et al., 2007). In brief, phospho-Stat5 was immunoprecipitated from pervana-
date-treated Daudi cells and incubated with GST-tagged proteins in 25 mM
HEPES (pH 7.5), 5 mM EDTA, and 10 mM DTT at 30C for 1 hr. GST-SHP-1
WT or D419A mutant was phosphorylated by Lyn precipitated from Ba/F3 cells
in vitro.
Human Samples
Peripheral blood samples were collected from patients with human hemato-
poietic malignancies. Leukocytes were lysed in SDS sample buffer and
analyzed by western blotting. The study protocols were approved by the
Human Subjects Research Ethics Board of the University of Western Ontario.
Informed consent was obtained from each study subject.
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Experimental Procedures, 13
figures, and six tables and can be found with this article online at http://
www.cell.com/cancer-cell/supplemental/S1535-6108(09)00182-2.170 Cancer Cell 16, 161–171, August 4, 2009 ª2009 Elsevier Inc.ACKNOWLEDGMENTS
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